NZ625543B2 - Sterilization process - Google Patents
Sterilization process Download PDFInfo
- Publication number
- NZ625543B2 NZ625543B2 NZ625543A NZ62554312A NZ625543B2 NZ 625543 B2 NZ625543 B2 NZ 625543B2 NZ 625543 A NZ625543 A NZ 625543A NZ 62554312 A NZ62554312 A NZ 62554312A NZ 625543 B2 NZ625543 B2 NZ 625543B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- biomaterial
- tissue
- solution
- cross
- collagen
- Prior art date
Links
- 230000001954 sterilising Effects 0.000 title claims abstract description 83
- 238000004659 sterilization and disinfection Methods 0.000 title claims abstract description 72
- 238000000034 method Methods 0.000 title abstract description 22
- 239000000560 biocompatible material Substances 0.000 claims abstract description 161
- 102000008186 Collagen Human genes 0.000 claims abstract description 114
- 108010035532 Collagen Proteins 0.000 claims abstract description 114
- 229920001436 collagen Polymers 0.000 claims abstract description 114
- 229960005188 collagen Drugs 0.000 claims abstract description 114
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 94
- GOOHAUXETOMSMM-UHFFFAOYSA-N propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 claims abstract description 73
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims abstract description 20
- 210000001519 tissues Anatomy 0.000 claims description 136
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims description 45
- 210000003709 Heart Valves Anatomy 0.000 claims description 17
- 210000003516 Pericardium Anatomy 0.000 claims description 13
- 241000283690 Bos taurus Species 0.000 claims description 11
- 210000002808 Connective Tissue Anatomy 0.000 claims description 8
- 229920000642 polymer Polymers 0.000 claims description 8
- 210000000988 Bone and Bones Anatomy 0.000 claims description 7
- 241000283073 Equus caballus Species 0.000 claims description 7
- 210000002216 Heart Anatomy 0.000 claims description 7
- GNSKLFRGEWLPPA-UHFFFAOYSA-M Monopotassium phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 claims description 7
- 230000000271 cardiovascular Effects 0.000 claims description 6
- 230000001413 cellular Effects 0.000 claims description 6
- 210000004204 Blood Vessels Anatomy 0.000 claims description 5
- 210000000845 Cartilage Anatomy 0.000 claims description 5
- 210000003041 Ligaments Anatomy 0.000 claims description 5
- 210000002435 Tendons Anatomy 0.000 claims description 5
- 230000002500 effect on skin Effects 0.000 claims description 5
- 229920001059 synthetic polymer Polymers 0.000 claims description 5
- 210000001951 Dura Mater Anatomy 0.000 claims description 4
- 230000002792 vascular Effects 0.000 claims description 4
- 210000003491 Skin Anatomy 0.000 claims description 3
- 230000002829 reduced Effects 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 238000011065 in-situ storage Methods 0.000 claims description 2
- 238000003860 storage Methods 0.000 abstract description 24
- 239000000243 solution Substances 0.000 description 111
- 235000019441 ethanol Nutrition 0.000 description 75
- 239000011575 calcium Substances 0.000 description 50
- 230000002308 calcification Effects 0.000 description 29
- 238000004132 cross linking Methods 0.000 description 29
- 239000003431 cross linking reagent Substances 0.000 description 23
- 210000001765 Aortic Valve Anatomy 0.000 description 22
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 22
- 229910052791 calcium Inorganic materials 0.000 description 22
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 22
- 239000011780 sodium chloride Substances 0.000 description 19
- 230000000694 effects Effects 0.000 description 17
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 239000003929 acidic solution Substances 0.000 description 13
- 150000001299 aldehydes Chemical class 0.000 description 12
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbamate Chemical compound NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 12
- AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical compound C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 description 10
- 210000004215 spores Anatomy 0.000 description 10
- 235000014469 Bacillus subtilis Nutrition 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 239000012487 rinsing solution Substances 0.000 description 9
- 239000002253 acid Substances 0.000 description 8
- 125000003277 amino group Chemical group 0.000 description 8
- 239000008367 deionised water Substances 0.000 description 8
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- -1 N-substituted maleimides Chemical class 0.000 description 7
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N PMSF Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 7
- 230000015556 catabolic process Effects 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 230000004059 degradation Effects 0.000 description 7
- 238000006731 degradation reaction Methods 0.000 description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 7
- MKRTXPORKIRPDG-UHFFFAOYSA-N Diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 6
- 102000016942 Elastin Human genes 0.000 description 6
- 108010014258 Elastin Proteins 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N Isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 6
- 210000004027 cells Anatomy 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 229920002549 elastin Polymers 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 238000002513 implantation Methods 0.000 description 5
- 239000008363 phosphate buffer Substances 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- BTANRVKWQNVYAZ-UHFFFAOYSA-N 2-Butanol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 4
- 240000008371 Bacillus subtilis Species 0.000 description 4
- 229940075615 Bacillus subtilis Drugs 0.000 description 4
- 210000004369 Blood Anatomy 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 4
- 229920001850 Nucleic acid sequence Polymers 0.000 description 4
- 241000700157 Rattus norvegicus Species 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 238000003321 atomic absorption spectrophotometry Methods 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 150000001718 carbodiimides Chemical class 0.000 description 4
- 238000011109 contamination Methods 0.000 description 4
- 230000002255 enzymatic Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N n-butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- DKGAVHZHDRPRBM-UHFFFAOYSA-N t-BuOH Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 229920001744 Polyaldehyde Polymers 0.000 description 3
- 230000001464 adherent Effects 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000010382 chemical cross-linking Methods 0.000 description 3
- 150000002170 ethers Chemical class 0.000 description 3
- ZHNUHDYFZUAESO-UHFFFAOYSA-N formamide Substances NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 3
- 210000000056 organs Anatomy 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- XSCDOEBLKZJZLX-UHFFFAOYSA-N 1-ethenylsulfonylethene;2-hydroxyethyl 2-methylprop-2-enoate Chemical compound C=CS(=O)(=O)C=C.CC(=C)C(=O)OCCO XSCDOEBLKZJZLX-UHFFFAOYSA-N 0.000 description 2
- 210000003815 Abdominal Wall Anatomy 0.000 description 2
- 241001466804 Carnivora Species 0.000 description 2
- HPXRVTGHNJAIIH-UHFFFAOYSA-N Cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 2
- AZKVWQKMDGGDSV-BCMRRPTOSA-N Genipin Chemical compound COC(=O)C1=CO[C@@H](O)[C@@H]2C(CO)=CC[C@H]12 AZKVWQKMDGGDSV-BCMRRPTOSA-N 0.000 description 2
- 229960002885 Histidine Drugs 0.000 description 2
- QWPPOHNGKGFGJK-UHFFFAOYSA-N Hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- 241000283953 Lagomorpha Species 0.000 description 2
- 241000289419 Metatheria Species 0.000 description 2
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-hydroxy-Succinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
- GYHFUZHODSMOHU-UHFFFAOYSA-N Nonanal Chemical compound CCCCCCCCC=O GYHFUZHODSMOHU-UHFFFAOYSA-N 0.000 description 2
- 241000283898 Ovis Species 0.000 description 2
- 241000283089 Perissodactyla Species 0.000 description 2
- 239000004952 Polyamide Substances 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 241001493546 Suina Species 0.000 description 2
- 241000287433 Turdus Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 150000001350 alkyl halides Chemical group 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 150000001502 aryl halides Chemical class 0.000 description 2
- 230000001588 bifunctional Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 125000003700 epoxy group Chemical group 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 150000002463 imido esters Chemical class 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 230000000415 inactivating Effects 0.000 description 2
- 230000001965 increased Effects 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 150000002513 isocyanates Chemical class 0.000 description 2
- 230000000670 limiting Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N n-pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000001717 pathogenic Effects 0.000 description 2
- 239000012466 permeate Substances 0.000 description 2
- 229920002647 polyamide Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propanol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 231100000803 sterility Toxicity 0.000 description 2
- 239000003206 sterilizing agent Substances 0.000 description 2
- 200000000020 tissue injury Diseases 0.000 description 2
- 230000002588 toxic Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000009941 weaving Methods 0.000 description 2
- OGDDUPYYEQZVHV-KDDYFZQKSA-N (2S)-2-amino-5-(diaminomethylideneamino)pentanoic acid;(2S)-2,6-diaminohexanoic acid Chemical compound NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCCNC(N)=N OGDDUPYYEQZVHV-KDDYFZQKSA-N 0.000 description 1
- PWAXUOGZOSVGBO-UHFFFAOYSA-N Adipoyl chloride Chemical compound ClC(=O)CCCCC(Cl)=O PWAXUOGZOSVGBO-UHFFFAOYSA-N 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- 241000974482 Aricia saepiolus Species 0.000 description 1
- 210000001367 Arteries Anatomy 0.000 description 1
- 210000001772 Blood Platelets Anatomy 0.000 description 1
- 210000001124 Body Fluids Anatomy 0.000 description 1
- GKWCCSUCDFFLBP-UHFFFAOYSA-N C1CO1.C1CO1 Chemical group C1CO1.C1CO1 GKWCCSUCDFFLBP-UHFFFAOYSA-N 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 240000008886 Ceratonia siliqua Species 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- 229960003260 Chlorhexidine Drugs 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Exidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- 210000002744 Extracellular Matrix Anatomy 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N Glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 1
- 229940015043 Glyoxal Drugs 0.000 description 1
- RRAMGCGOFNQTLD-UHFFFAOYSA-N Hexamethylene diisocyanate Chemical compound O=C=NCCCCCCN=C=O RRAMGCGOFNQTLD-UHFFFAOYSA-N 0.000 description 1
- 239000005057 Hexamethylene diisocyanate Substances 0.000 description 1
- 210000004731 Jugular Veins Anatomy 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 210000003734 Kidney Anatomy 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 210000003903 Pelvic Floor Anatomy 0.000 description 1
- 210000002381 Plasma Anatomy 0.000 description 1
- 241001272996 Polyphylla fullo Species 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- GOOHAUXETOMSMM-VKHMYHEASA-N S-propylene oxide Chemical compound C[C@H]1CO1 GOOHAUXETOMSMM-VKHMYHEASA-N 0.000 description 1
- 241000219289 Silene Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 206010068760 Ulcers Diseases 0.000 description 1
- 230000036462 Unbound Effects 0.000 description 1
- 210000001635 Urinary Tract Anatomy 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 230000002730 additional Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive Effects 0.000 description 1
- 230000001058 adult Effects 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 239000002473 artificial blood Substances 0.000 description 1
- 210000004666 bacterial spores Anatomy 0.000 description 1
- 238000010364 biochemical engineering Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229960002798 cetrimide Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 201000009910 diseases by infectious agent Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 102000034337 fibrous proteins Human genes 0.000 description 1
- 108091005892 fibrous proteins Proteins 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- KSKYTIWOGUMFTK-UHFFFAOYSA-N formaldehyde;pentanedial Chemical compound O=C.O=CCCCC=O KSKYTIWOGUMFTK-UHFFFAOYSA-N 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000004676 glycans Polymers 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002209 hydrophobic Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000000984 immunochemical Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular Effects 0.000 description 1
- 230000000366 juvenile Effects 0.000 description 1
- 238000009940 knitting Methods 0.000 description 1
- 230000003902 lesions Effects 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 230000000813 microbial Effects 0.000 description 1
- 230000003278 mimic Effects 0.000 description 1
- 230000000116 mitigating Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000000399 orthopedic Effects 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N oxane Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 230000036961 partial Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) polymer Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000001225 therapeutic Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 238000005429 turbidity Methods 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/10—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0082—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using chemical substances
- A61L2/0088—Liquid substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
- A61L2/18—Liquid substances or solutions comprising solids or dissolved gases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2202/00—Aspects relating to methods or apparatus for disinfecting or sterilising materials or objects
- A61L2202/20—Targets to be treated
- A61L2202/21—Pharmaceuticals, e.g. medicaments, artificial body parts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/02—Treatment of implants to prevent calcification or mineralisation in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/20—Materials or treatment for tissue regeneration for reconstruction of the heart, e.g. heart valves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/24—Collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
- A61L27/3687—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by the use of chemical agents in the treatment, e.g. specific enzymes, detergents, capping agents, crosslinkers, anticalcification agents
Abstract
Disclosed herein is a process for sterilizing implantable biomaterials comprising contacting said cross-linked collagen-based biomaterial with a sterilization solution comprising between 3% and 6% v/v propylene oxide and incubating said biomaterial between 30°C and 55°C for greater than 48 hours; with the proviso that the sterilization solution does not include alcohol. Also disclosed is the storage of the biomaterial in the propylene oxide solution wherein the propylene oxide is converted to propylene glycol. th the proviso that the sterilization solution does not include alcohol. Also disclosed is the storage of the biomaterial in the propylene oxide solution wherein the propylene oxide is converted to propylene glycol.
Description
STERILIZATION PROCESS
FIELD
The present invention relates to a process for sterilizing implantable biomaterials. In particular,
the invention relates to a process for sterilizing collagen-containing implantable biomaterials
and storage thereafter.
BACKGROUND
Implantable biomaterials, especially collagen-based biomaterials, require sterilization and most
often storage before use. Generally there are two broad classes of implantable collagen-based
biomaterials: (1) natural tissue and (2) chemically cross-linked tissue. Thus, depending upon
the type of collagen-based biomaterial and whether or not cross-linking has taken place there is
a need for a means of sterilizing the tissue as well as storing tissue once it has been sterilized.
Chemical cross-linked collagen-based biomaterials such as cardiovascular patches, heart valves,
matrices and arteries are usually sterilized after cross-linking and stored in a sterile solution
until implantation. Several sterilization methods for chemical cross-linked collagen-based
biomaterials have been tested and implemented over the past three to four decades including
gamma irradiation, UV irradiation and a variety of chemical agents. Although most of these
sterilization methods are efficient in preventing contamination, adverse effects such as
structural damage (cleaving of peptide bonds) and tissue degeneration (reduction in tensile
strength) has made a number of these methods less appealing for industrial application.
For example, collagen-based biomaterials cross-linked with glutaraldehyde can become
chemically unstable when exposed to alcohol-based sterilisation solutions due to the interaction
of the alcohol with residual and unbound glutaraldehyde present in the tissue. Unstable
hemiacetyls are formed when an alcohol reacts with an aldehyde. These unstable hemiacetyls
have the capacity to react with alcohol to form an acetyl, which can dissociate to form an
aldehyde and an alcohol.
Thus, at present, the majority of manufacturers of collagen-based biomaterials prefer the use of
glutaraldehyde-formaldehyde combinations for chemical cross-linking and non-aldehyde agents
for sterilization. One such non-aldehyde agent is ethylene oxide (oxirane) gas, which has been
5327735_1 (GHMatters) P88608.NZ
used to sterilize mechanical heart valves for many years. Ethylene oxide gas has also been used
to sterilize a variety of medical equipment, disposable items and mechanical heart valves.
Once the collagen-based biomaterial has been sterilized it is generally stored for a period of
time before implantation. Mid- to long-term storage of collagen-based biomaterials requires
adequate protection from contamination in a physiologically, stable solution. Although most of
the commercially available collagen-based biomaterials are still stored in aldehyde-based
solutions, adverse effects such as calcification and fibrosis are well known.
Since the 1970’s propylene oxide has been used as a sterilizing agent (see, for example, Hart &
Brown, 1974, Appl Microbiol, Dec. p.1069-1070; Brown & Ng, 1975, Appl Microbiol, Sept.
p483-484). In each case a solution comprising 5% propylene oxide plus 70% isopropyl alcohol
or 0.5% chlorhexidine or 2% Cetrimide was effective in destroying a bacterial spore
suspension. However, while the use of propylene oxide has been recorded this is usually applied
in the presence of alcohol (ethanol or isopropanol). Thus, the use of an alcohol as an additive to
propylene oxide sterilisation with aldehyde cross-linked tissues (containing residual aldehydes)
could result in elevated aldehyde levels, which in turn increases the calcification potential of
these tissues and ultimately bioprosthetic failure.
Consequently, what is required is an efficient sterilization process which not only sterilizes
chemical cross-linked collagen-based biomaterials, but also provides a convenient storage
medium for the sterilized biomaterial.
SUMMARY
The inventors have developed a process that overcomes or at least alleviates the problems
associated with typically used sterilization and/or storage methods for cross-linked collagen-
based biomaterials.
Accordingly, in a first aspect the present invention provides a method for sterilizing a cross-
linked collagen-based biomaterial comprising contacting said cross-linked collagen-based
biomaterial with a sterilization solution comprising between 3% and 6% v/v propylene oxide
and incubating said biomaterial between 30 C and 55 C for greater than 48 hours; with the
proviso that the sterilization solution does not include alcohol.
In some embodiments the incubation temperature is between 30 C, 31 C, 32C, 33C, 34C,
5327735_1 (GHMatters) P88608.NZ
C, 36C, 37C, 38 C, 39C, 40C, 41C, 42 C, 43 C, 44C, 45 C, 46C, 47C, 48C, 49C,
50C, 51C, 52C, 53 C, 54C and 55 C. In other embodiments the incubation temperature is
between 30 C and 31 C, 32 C, 33C, 34 C, 35 C, 36C, 37 C, 38C, 39C, 40 C, 41C, 42 C,
43C, 44C, 45C, 46 C, 47C, 48C, 49C, 50 C, 51 C, 52C, 53 C, 54C or 55 C. In other
words, all combinations of temperatures between the range 30C and 55 C are envisaged. In
some embodiments the incubation temperature is preferably between 35 C and 50 C, more
preferably between 40 C and 48C. In some embodiments the incubation temperature is about
45C.
Once the incubation period has lapsed i.e. more than 48 hours have elapsed it is permissible to
allow the temperature to reduce to room temperature. Indeed, the sterilized cross-linked
collagen-based biomaterial can remain at room temperature for some time after the initial 48
hours as at this time. Once the sterilized cross-linked collagen-based biomaterial has been
incubated in the propylene oxide for at least 4 days the propylene oxide will have been
converted to propylene glycol and the collagen-based biomaterial will be ready to use.
In some embodiments, the sterilization solution comprises between 3.8% and 4.5% v/v
propylene oxide. In other embodiments, the sterilization solution comprises about 4% v/v
propylene oxide. In some embodiments, the sterilization solution consists essentially of between
3% and 6% v/v propylene oxide, more preferably the sterilization solution consists of between
3% and 6% v/v propylene oxide. In some embodiments, the sterilization solution consists
essentially of between 3.8% and 4.5% v/v propylene oxide, more preferably the sterilization
solution consists of between 3.8% and 4.5% v/v propylene oxide. In some embodiments, the
sterilization solution consists essentially of about 4% v/v propylene oxide, more preferably the
sterilization solution consists of about 4% v/v propylene oxide.
It will be appreciated that alcohol, especially ethanol and/or isopropanol is not used in the
sterilization solution of the present invention.
It is a requirement that the sterilization step is carried out for greater than 48 hours (2 days);
however, as the sterilization solution can also be used as a storage medium the sterilization step
can be carried out for 2, 3, 4, 5, 6, 7, 8, 9, 10 or more days.
The cross-linked collagen-based biomaterial can be any material which comprises, consists
essentially of or consists of collagen. In some embodiments, the collagen-based biomaterial is
isolated directly from an animal. The biomaterial can be isolated from any animal, whether
5327735_1 (GHMatters) P88608.NZ
from the same species as a recipient or from an animal of a different species to the recipient.
Preferably, the animal is from one of the mammalian orders i.e. Artiodactyla, Lagomorpha,
Rodentia, Perissodactyla, Carnivora and Marsupialia. More preferably, the animal is selected
from the group consisting of an ovine, a bovine, a caprine, an equine, a porcine, a marsupial and
a human.
The biomaterial may be any type of cellular tissue. Preferably, the cellular tissue is selected
from the group consisting cardiovascular tissue, heart tissue, heart valve, aortic roots, aortic
wall, aortic leaflets, pericardial tissue, connective tissue, dura mater, dermal tissue, a vascular
tissue, cartilage, pericardium, ligament, tendon, blood vessels, umbilical tissue, bone tissue,
fasciae, and submucosal tissue and skin.
In some embodiments, the biomaterial is and/or comprises discrete i.e. isolated collagen, rather
than a naturally-occurring collagen-containing tissue. The discrete collagen may be used in its
isolated state or formed into any medical device or article known in the art.
In some embodiments, the biomaterial is a cultured tissue, a prosthesis containing extra-cellular
matrix obtained from an animal, a reconstituted tissue (e.g. collagen matrix), or the like.
It will also be appreciated that the biomaterial might further comprise synthetic analogs formed
from synthetic polymers, biological polymers, or both, including those generally found in
natural tissue matrices. Suitable synthetic polymers include, for example, polyamides and
polysulphones. Biological polymers can be naturally occurring or produced in vitro by, for
example, fermentation and the like.
In a second aspect, the present invention provides a method for sterilizing a collagen-based
biomaterial comprising:
(a) providing a collagen-based biomaterial and washing same with ice-cold 0.9%
v/v saline solution and placing said biomaterial in ice-cold 0.9% v/v saline / Phenyl-methyl-
sulfonyl-fluoride (PMSF);
(b) contacting said collagen-based biomaterial with 0.625% v/v glutaraldehyde
solution and potassium di-hydrogen phosphate pH 7.4 and incubating same at about 1-5 C for
at least 5 days to produce a cross-linked collagen-based biomaterial;
(c) rinsing said cross-linked collagen-based biomaterial in sterile 0.9% v/v sodium
chloride at approximately 10 C and then contacting the cross-linked collagen-based biomaterial
with a sterilization solution comprising between 3.8% and 4.5% v/v propylene oxide and
5327735_1 (GHMatters) P88608.NZ
incubating said tissue between 30 C and 55 C for greater than 48 hours; with the proviso that
the sterilization solution does not include alcohol.
In a third aspect the present invention provides a method for storing a sterilized, cross-linked
collagen-based biomaterial comprising contacting a cross-linked collagen-based biomaterial
with a solution comprising between 3% and 6% v/v propylene oxide and incubating said
biomaterial between 30 C and 55 C for greater than 48 hours and then allowing the biomaterial
to remain in contact with said propylene oxide until same converts to propylene glycol; with the
proviso that the solution does not include alcohol.
In a fourth aspect, the present invention provides a sterilized, cross-linked collagen-based
biomaterial produced by a method according to the first, second or third aspects.
It will be appreciated that once the sterilized, cross-linked collagen-based biomaterial has been
obtained by the methods of the present invention it can be included with implantable biological
devices. Accordingly, in a fifth aspect, the present invention provides an implantable biological
device comprising a sterilized, cross-linked collagen-based biomaterial according to the fourth
aspect.
In a further aspect of the present invention the cross-linked collagen-based biomaterial of the
present invention is contained within a kit for repairing a tissue injury. Thus, in a sixth aspect
the present invention provides a kit for repairing a tissue injury comprising:
(a) a sterile container having a sterilized, cross-linked collagen-based biomaterial
according to the fourth aspect or a device according to the fifth aspect; and
(b) instructions for use on an injured subject.
In a seventh aspect, the present invention provides a container comprising a sterilized, cross-
linked collagen-based biomaterial and a 3% to 6% v/v propylene glycol solution, wherein said
propylene glycol has resulted from the conversion in situ of a 3% to 6% v/v propylene oxide
solution while in the presence of the biomaterial.
The collagen-based biomaterial of the present invention may be cross-linked by any method
know in the art of cross-linking collagen including, but not limited to, the methods disclosed in
Eyre et al., 1984, Annu. Rev. Biochem. 537, 717-748; Eyre, 1982, In: Symposium on Heritable
Disorders of Connective Tissue (Akeson et al. eds) pp. 43-58, Mosby, St. Louis, Missouri;
Davison & Brennan, 1983, Connect. Tissue Res. 11, 135-151; Robins, 1982, Methods Biochem.
5327735_1 (GHMatters) P88608.NZ
Analysis, 28, 330-379; Reiser, 1991, Proc. Soc. Exp. Biol. Med. 196, 17-29; all of which are
incorporated herein in their entirety by reference. However, a preferred method of cross-linking
the collagen-based biomaterial of the present invention comprises:
(a) exposing a collagen-based biomaterial to an alcohol-containing solution for at
least 24 hours;
(b) exposing said biomaterial in step (a) to a cross-linking agent; and
(c) exposing said biomaterial in step (b) to an acidic solution;
wherein step (b) and (c) are sequential to step (a).
The alcohol-containing solution used in step (a) is preferably a water-based liquid i.e. is an
aqueous solution of greater than about 50% v/v alcohol, and preferably between 60% to 80%
alcohol by volume. Either buffered or non-buffered alcohol-containing solution can be used;
however, it is preferable that a non-buffered alcohol-containing solution is used as it has been
found that buffered alcohol-containing solutions adversely affect subsequent cross-linking
procedures producing a yellowed biomaterial.
The preferred method of cross-linking can use any alcohol known in art in the alcohol-
containing solution. Preferably, the alcohol is a C -C lower alcohol in a buffer-free solution.
Even more preferably, the alcohol is selected from the group consisting of methanol, ethanol,
cyclohexanol, isopropanol, propanol, butanol, pentanol, isobutanol, sec-butanol and t-butanol.
In some embodiments, the alcohol-containing solution comprises a mixture of two or more
alcohols provided that the combined volume of the alcohol is greater than 50% v/v. For
example, a mixture of about 70% v/v ethanol and about 10% v/v isobutanol is effective.
The biomaterial in step (a) can be exposed to the alcohol-containing solution for any length of
time as long as it is sufficient to render the biomaterial resistant to in vivo pathogenic
calcification. Preferably, the biomaterial remains in contact with the alcohol-containing solution
for sufficient time to enable the alcohol to diffuse and permeate into the biomaterial. More
preferably, the biomaterial is exposed to the alcohol-containing solution for at least 24 hours,
even more preferably at least 36 hours and most preferably, at least 48 hours.
The biomaterial, after exposure to the alcohol-containing solution, is removed and exposed to
one or more cross-linking agents. Any form of cross-linking agent known in the art or
combination thereof may be used as long as it is capable of cross-linking collagen. Accordingly,
it will be appreciated that cross-linking agents, include but are not limited to, divinyl sulfone
5327735_1 (GHMatters) P88608.NZ
(DVS), polyethylene glycol divinyl sulfone (VS-PEG-VS), hydroxyethyl methacrylate divinyl
sulfone (HEMA-DIS-HEMA), formaldehyde, glutaraldehyde, aldehydes, isocyanates, alkyl and
aryl halides, imidoesters, N-substituted maleimides, acylating compounds, carbodiimide,
hydroxychloride, N-hydroxysuccinimide, light (e.g., blue light and UV light), pH, temperature,
and combinations thereof. Preferably, the cross-linking agent is a chemical cross-linking agent
selected from the group consisting of carbodiimide, polyepoxy ethers, divinyl sulfone (DVS),
polyaldehyde and diphenylphosphoryl azide (DPPA).
In some embodiments, the polyaldehyde is a bi-, tri- or di-aldehyde. Glutaraldehyde is
especially preferred.
In some embodiments, the cross-linking step (b) is followed by step (c), with or without an
intervening wash step. The acidic solution used in step (c) contains any acid capable of
inactivating and/or modifying the fixed and/or unfixed cross-linking agent moieties present in
the biomaterial after step (b) to remove or reduce available calcium binding sites. Alternatively,
or in addition to, the acidic solution used in step (c) contains any acid capable of further cross-
linking the activated carboxyl groups with the activated amine groups on the collagen to form
amide bonds. Preferably, the acid in the acidic solution comprises an aminocarboxylic acid.
Preferably, the aminocarboxylic acid is an acid having at least one amino group and at least one
carboxylic acid substituent. More preferably, the aminocarboxylic acid is selected from the
group consisting of L-arginine, L-lysine, L-histidine, L-glutamate or L-aspartate.
The step of rinsing the biomaterial is conducted using a phosphate-free solution of 0.9% v/v
saline.
While it will be appreciated by those skilled in the art that the temperature at which each of the
steps in the preferred cross-linking method is carried out is not critical, it will be understood
that preferably, the temperature is between 2 C and 40 C, more preferably, between 4 C and
C and most preferably, between 5 C and 25 C.
In one embodiment, the alcohol, acidic solution and rinsing solution are all buffer-free.
BRIEF DESCRIPTION OF THE FIGURES
Figure 1 shows the effect of 2% propylene oxide at varying temperatures between 15°C and
45°C on B. subtilis spores over time.
5327735_1 (GHMatters) P88608.NZ
Figure 2 shows the effect of 4% propylene oxide at varying temperatures between 15°C and
45°C on B. subtilis spores over time.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
Before describing the present invention in detail, it is to be understood that this invention is not
limited to particularly exemplified methods of production, which may, of course, vary. It is also
to be understood that the terminology used herein is for the purpose of describing particular
embodiments of the invention only, and is not intended to be limiting which will be limited only
by the appended claims.
All publications, patents and patent applications cited herein, whether supra or infra, are hereby
incorporated by reference in their entirety. However, publications mentioned herein are cited for
the purpose of describing and disclosing the protocols and reagents which are reported in the
publications and which might be used in connection with the invention. Nothing herein is to be
construed as an admission that the invention is not entitled to antedate such disclosure by virtue
of prior invention.
Furthermore, the practice of the present invention employs, unless otherwise indicated,
conventional immunological techniques, chemistry and pharmacology within the skill of the art.
Such techniques are well known to the skilled worker, and are explained fully in the literature.
See, e.g., Coligan, Dunn, Ploegh, Speicher and Wingfield “Current protocols in Protein
Science” (1999) Volume I and II (John Wiley & Sons Inc.); and Bailey, J.E. and Ollis, D.F.,
Biochemical Engineering Fundamentals, McGraw-Hill Book Company, NY, 1986;
Immunochemical Methods In Cell And Molecular Biology (Mayer and Walker, eds., Academic
Press, London, 1987); Handbook Of Experimental Immunology, Volumes I-IV (D. M. Weir
and C. C. Blackwell, eds., 1986).
It must be noted that as used herein and in the appended claims, the singular forms “a,” “an,”
and “the” include plural reference unless the context clearly dictates otherwise. Thus, for
example, a reference to “a cross-linking agent” includes a plurality of such agents, and a
reference to “an alcohol” is a reference to one or more alcohols, and so forth. Unless defined
otherwise, all technical and scientific terms used herein have the same meanings as commonly
understood by one of ordinary skill in the art to which this invention belongs. Although any
5327735_1 (GHMatters) P88608.NZ
materials and methods similar or equivalent to those described herein can be used to practice or
test the present invention, the preferred materials and methods are now described.
In one of the broadest aspects, the present invention relates to a method for sterilizing a
collagen-based biomaterial.
As used herein, the term “biomaterial” refers to any collagen containing material that
potentially has a biological use. The collagen might be any type of collagen from any source
and might be present alone or in combination with other materials. Accordingly, the collagen
might represent as little as 1% w/w of the total weight of the biomaterial or as much as 100%.
The term “collagen” as used herein refers to the extracellular family of fibrous proteins that are
characterised by their stiff, triple-stranded helical structure. Three collagen polypeptide chains
(“ -chains”) are wound around each other to form this helical molecule. The term is also
intended to encompass the various types of collagen.
The major portion of the helical portion of collagen varies little between mammalian species.
Indeed, a number of collagen types have high degrees of nucleotide and amino acid sequence
homologies. For example, the nucleotide sequence homology for collagen alpha I type II is at
least 88% when comparing humans, equines and murine. Humans and equines have 93%
sequence homology at the nucleotide level, while mouse and equine have 89% sequence
homology. The nucleotide sequence homology for human and mouse is 88% (see, NCBI
accession numbers U62528 (Equine), NM033150 (Human) and NM031163 (mouse)
http://www.ncbi.nlm.nih.gov). Other types of collagen have similar levels of amino acid
homology. For example, the nucleotide sequence homology between porcine collagen alpha I
type I and ovine collagen alpha I type I is 90% (see, NCBI accession numbers AF29287
(Ovine) and AF201723 (Porcine) http://www.ncbi.nlm.nih.gov).
Given the level of common ancestry and biology for many of the above animals, the high
degree of amino acid and nucleotide sequence homology for collagen across a number of
species such as cattle, sheep, mice and pigs, a person skilled in the art would appreciate that the
methods for producing the biomaterial as disclosed herein are applicable for collagenous
material isolated from all mammalian animals.
Accordingly, in some embodiments, the biomaterial is isolated or harvested from an animal of
one of the mammalian orders i.e. Artiodactyla, Lagomorpha, Rodentia, Perissodactyla,
5327735_1 (GHMatters) P88608.NZ
Carnivora and Marsupialia. The animal is preferably an ovine, a bovine, a caprine, an equine,
a porcine, a marsupial or a human. While the biomaterial is preferably isolated from the same
animal species as the recipient, it is envisaged that the biomaterial might be isolated from a
different species to the recipient.
Alternatively, in some embodiments, the biomaterial comprises a cultured tissue, a reconstituted
tissue or the like.
The biomaterial might be any type of cellular tissue. For example, the cellular tissue might be
cardiovascular tissue, pelvic floor tissue, heart tissue, heart valve, aortic roots, aortic wall, aortic
leaflets, pericardial tissue, connective tissue, the matrix of soft or solid organs, dermal tissue, a
vascular tissue, dura mater, cartilage, pericardium, ligament, tendon blood vessels, umbilical
tissue, bone tissue, fasciae, and submucosal tissue or skin as all of these comprises some
collagen.
It will also be appreciated that the biomaterial might further comprise synthetic analogs formed
from synthetic polymers, purified biological polymers, or both, including those generally found
in natural tissue matrices. Suitable synthetic polymers include, for example, polyamides and
polysulphones. Biological polymers can be naturally occurring or produced in vitro by, for
example, fermentation and the like.
Purified biological polymers can be appropriately formed into a substrate by techniques such as
weaving, knitting, casting, moulding, extrusion, cellular alignment, and magnetic alignment.
Suitable biological polymers include, without limitation, collagen, elastin, silk, keratin, gelatin,
polyamino acids, polysaccharides (e.g. cellulose and starch), and copolymers of any of these.
For example, collagen and elastin polymers can be formed into a synthetic implantable material
by any of a variety of techniques, such as weaving and moulding. Synthetic tissue analogs
mimic a natural tissue matrix. Alternatively, synthetic substrates can be used to form a tissue
analog, either alone or together with naturally occurring substrates Non-limiting examples
include, polypropylene, polylactic acid, polyester, nylon, silicone and the like.
Once the biomaterial has been acquired it is cross-linked. The cross-linking can utilize any of
the well known procedures including, but not limited to, those described in Eyre et al., 1984,
Annu. Rev. Biochem. 537, 717-748; Eyre, 1982, In: Symposium on Heritable Disorders of
Connective Tissue (Akeson et al. eds) pp. 43-58, Mosby, St. Louis, Missouri; Davison &
5327735_1 (GHMatters) P88608.NZ
Brennan, 1983, Connect. Tissue Res. 11, 135-151; Robins, 1982, Methods Biochem. Analysis
28, 330-379; Reiser, 1991, Proc. Soc. Exp. Biol. Med. 196, 17-29.
A preferred method of cross-linking is disclosed in the Applicants International Patent
Application WO2006/066327 incorporated herein in its entirety by reference. Briefly, an initial
step in the preferred method of cross-linking the collagen-based biomaterial of the present
invention comprises contacting the biomaterial with an alcohol-containing solution. As used
herein, the term “contacted,” or “contacting” refers to the active step of immersing the collagen-
based biomaterial in a solution or agent as described here, or as described infra, subsequently
contacting the biomaterial with a cross-linking agent, an acidic solution or other matter for a
sufficient period of time to bring about a desired outcome. Methods for contacting the
biomaterial with, for example, the alcohol-containing solution are well known in the art. For
example, in general, the biomaterial can be contacted by spraying, dipping or immersing the
biomaterial in a solution or agent.
The term “alcohol” as used herein refers to any alcohol known in art which is capable of
removing or reducing the amount of triglycerides and at least partially esterifying the carboxyl
groups found on collagen. Preferably, the alcohol is a water-soluble alcohol. More preferably,
the alcohol is a C -C lower alcohol in a buffer-free solution. Even more preferably, the alcohol
is selected from the group consisting of methanol, ethanol, cyclohexanol, isopropanol, propanol,
butanol, pentanol, isobutanol, sec-butanol and t-butanol.
Without wishing to be bound by any particular theory or hypothesis the inventors consider that
the alcohol-containing solution assists in loosening the collagen triple helix and thereby
exposing hydrophobic sites (see, Karube & Nishida, 1979, Biochim Biophys Acta., 23; 581(1):
106-13). They also consider that the carboxyl and amine groups found in collagen are esterified
in the presence of the alcohol-containing solution such that they become available for cross-
linking in later steps. As such, a preferred alcohol solution is one comprising at least about 50%
v/v, more preferably at least about 70% v/v and most preferably at least about 80% v/v alcohol
to buffer-free aqueous solution. In one embodiment, the alcohol solution is 70% ethanol v/v in
0.9% saline (containing 0.5mM PMSF)
In some embodiments the alcohol-containing solution, as well as other solutions and reagents
used herein are “buffer-free” as it is hypothesised that the cross-linking agents containing
aldehyde reacts with the buffer during fixation causing depolymerization of the aldehyde.
5327735_1 (GHMatters) P88608.NZ
The step of contacting the biomaterial to the alcohol-containing solution may be carried out for
any length of time as long as it is sufficient to render the biomaterial resistant to in vivo
pathogenic calcification and that the majority (i.e. a high percentage) of the carboxyl and amine
groups found in collagen are esterified. Preferably, the biomaterial remains in contact with the
alcohol-containing solution for sufficient time to enable the alcohol to diffuse and permeate into
the biomaterial. More preferably, the biomaterial is exposed to the alcohol-containing solution
for at least 24 hours, even more preferably at least 36 hours and most preferably, at least 48
hours.
Once the collagen-based biomaterial has been exposed to alcohol it is removed. In some
embodiments, the biomaterial is rinsed after the exposure to alcohol in a rinsing solution
comprising a phosphate-free solution of 0.9% v/v saline. However, any non-buffered
physiologically acceptable solution may be used as a rinsing solution. The purpose of the
rinsing solution is mainly to remove excess alcohol and as such is not critical.
After the collagen-based biomaterial has been exposed to alcohol for greater than 24 hours it is
then contacted with one or more cross-linking agents, especially bifunctional cross-linking
agents. The term “bifunctional” as used herein refers to the two functional aldehyde groups,
present at both ends of the five carbon chain. The cross-linking can be undertaken by any
technique known in the art, with any form of cross-linking agent as long as it is capable of
cross-linking collagen. Cross-linking agents, include but are not limited to, acylating
compounds, adipyl chloride, aldehydes, alkyl and aryl halides, bisimidates, carbodiimides,
divinyl sulfone (DVS), formaldehyde, glutaraldehyde, glyoxal, hexamethylene diisocyanate,
hydroxychloride, hydroxyethyl methacrylate divinyl sulfone (HEMA-DIS-HEMA),
imidoesters, isocyanates, light (e.g. blue light and UV light), N-hydroxysuccinimide, N-
substituted maleimides, pH, polyaldehyde, diphenylphosphoryl azide (DPPA), polyepoxy
compounds comprising backbone of 17-25 carbons and 4-5 epoxy groups, polyepoxy ethers,
polyethylene glycol divinyl sulfone (VS-PEG-VS), polyglycerol polyglycidyl ether and
temperature and combinations thereof.
In some embodiments, the cross-linking agent is a chemical cross-linking agent such as
carbodiimide, polyepoxy ethers, divinyl sulfone (DVS), genipin, glutaraldehyde, formaldehyde
and diphenylphosphoryl azide (DPPA).
It has also been demonstrated that polyepoxy compounds comprising backbone of 17-25
carbons and 4-5 epoxy groups show a high efficiency for the cross-linking collagen (see, for
5327735_1 (GHMatters) P88608.NZ
example, US Pat. Applic. No. 20040059430 (S/N 10/618,447). It has also been shown that the
toxicity of polyepoxy compounds is lower than that of glutaraldehyde, and the antigenicity or
immune-response induction of tissues decreases in proportion to the reaction time, in case of
reacting with helical polypeptide molecules such as collagen. Naturally, it shows relatively
good biocompatibility (see, for example, Lohre et al., (1992), Artif. Organs, 16:630-633;
Uematsu et al., (1998), Artif. Organs, 22:909-913). Consequently, polyepoxy compounds as
described are one preferred cross-linking agent.
In some embodiments, the cross-linking agent comprises about 1% glutaraldehyde and the
length of exposure is at least about 24 hours. It will be appreciated that the time length for
exposure of the biomaterial to the cross-linking agent depends on the agent used, the
concentration and the temperature. Typically, the length of exposure is between 24 hours to 28
days. The determination of the precise amount of exposure time for the biomaterial to the cross-
linking agent is well within the scope of a person skilled in the art.
Again, without wishing to be bound by any particular theory or hypothesis, the inventors
consider that by exposing the collagen-based biomaterial that has been exposed to alcohol to a
cross-linking agent, the esterified carboxyl groups and amine groups on the collagen present in
the biomaterial are cross-linked.
While it will be appreciated by those skilled in the art that the temperature at which each of the
steps of the preferred cross-linking method is carried out is not critical, it will be understood
that preferably, the temperature is between 2 C and 40 C, more preferably, between 4 C and
C and most preferably, between 5 C and 25 C.
Once again, after the cross-linking step, the collagen-based biomaterial is preferably rinsed in
rinsing solution such as that used after the alcohol exposure step (a). However, it will again be
appreciated that the rinsing step is merely a preferment.
Following the cross-linking step, or if utilised, the rinsing step after the cross-linking step, the
collagen-based biomaterial may then be sterilized for use by the methods described herein.
Alternatively, the collagen-based biomaterial is contacted with an acidic solution containing any
acid capable of inactivating and/or modifying the fixed and/or unfixed cross-linking agent
moieties present in the biomaterial after step (b) to remove or reduce available calcium binding
sites. Alternatively, or in addition to, the acidic solution used in step (c) contains any acid
capable of further cross-linking the activated carboxyl groups with the activated amine groups
5327735_1 (GHMatters) P88608.NZ
on the collagen to form amide bonds.
Preferably, the acidic solution comprises at least one aminocarboxylic acid. The term
“aminocarboxylic acid” as used herein is any acid having at least one amino group and at least
one carboxylic acid substituent. Representative examples of aminocarboxylic acids that are
useful in the present invention include, but are not limited to, L-glutamate, L-aspartate, L-lysine
L-arginine, L-histidine. The purpose of the acidic solution is two-fold: firstly, the
aminocarboxylic acid assists in the inactivation and/or modification of the fixed and unfixed
cross-linking agent moieties, thereby reducing or alleviating any adverse biological effects.
Secondly, the aminocarboxylic acid further cross-links the activated carboxyl groups with the
activated amine groups on the collagen to form amide bonds.
The concentration of the aminocarboxylic acid will depend upon the actual acid used and other
parameters such as total mass of the biomaterial used and the like. In addition, a minimum wet
weight ratio of aminocarboxylic acid to biomaterial would be about 1:4. The most important
aspect of the acidic solution is the pH. The pH must be below pH7, preferably below pH6, more
preferably below pH5 and most preferably below about pH4.6.
In one embodiment, the acidic solution is 8mg aminocarboxylic acid per millilitre of de-ionised
water, which is phosphate-free and about pH4.
The cross-linked collagen-based biomaterial is exposed to the aminocarboxylic acid for at least
6 hours, more preferably at least 24 hours, even more preferably more than 48 hours. While the
incubation temperature is not critical it is preferably between 5 C and 55 C, more preferably
between 10 C and 45 C, most preferably about 45 C.
In some embodiments, step (c) of the disclosed cross-linking method is replaced by or
supplemented with a method of inhibiting the formation of metalloproteinase on elastin
molecules present in the biomaterial. Specifically, in tissue such as aortic tissue a higher
percentage of elastin is present than in other tissue. These elastin molecules can provide sites
for the formation of metalloproteinase as such these sites need to be reduced, removed or
inactivated.
The cross-linked collagen-based biomaterial, before or after the step of exposing the biomaterial
to the acidic solution and/or buffer-free solution containing a multi-valent cation, is again
preferably rinsed in rinsing solution. The cross-linked collagen-based biomaterial is then
5327735_1 (GHMatters) P88608.NZ
sterilized.
The step of sterilizing the biomaterial comprises contacting the cross-linked collagen-based
biomaterial with a sterilization solution comprising between 3% and 6% v/v propylene oxide
and incubating said biomaterial between 30 C and 55 C for greater than 48 hours; with the
proviso that the sterilization solution does not include alcohol.
It will be appreciated that alcohol, especially ethanol and/or isopropanol is not used in the
sterilization solution of the present invention.
It has been well established that at elevated temperatures eg above 55 C, collagen undergoes
intracellular degradation. Indeed, it has been shown that collagen within human skin fibroblasts
starts to undergo increased degradation at temperatures above 41°C (Palotie, 1983, Coll Relat
Res. Mar; 3(2): 105-13). Thus, in sterilizing the cross-linked collagen-based biomaterial of the
present invention the temperature of incubation is a critical factor. The temperature is preferably
not greater than 55°C as this increases the chance that the collagen begins to degrade. However,
as described in Example 9 and elsewhere, it is important that the incubation temperature is not
less than 30°C as temperatures lower than 30°C have reduced sterilization potential.
It will be appreciated by persons skilled in the art that concentrations of propylene oxide below
3% would not provide sufficient sterilization as defined herein. Concentrations of propylene
oxide above 6% are toxic and have an adverse effect on the integrity of the biomaterial. In some
embodiments, the sterilization solution comprises between 3.8% and 4.5% propylene oxide. In
other embodiments, the sterilization solution comprises about 4% propylene oxide. In some
embodiments, the sterilization solution consists essentially of between 3% and 6% propylene
oxide, more preferably the sterilization solution consists of between 3% and 6% propylene
oxide. In some embodiments, the sterilization solution consists essentially of between 3.8% and
4.5% propylene oxide, more preferably the sterilization solution consists of between 3.8% and
4.5% propylene oxide. In some embodiments, the sterilization solution consists essentially of
about 4% propylene oxide, more preferably the sterilization solution consists of about 4%
propylene oxide.
The term “about” as used herein refers to a deviation in the value following the term by 10%
above or below. For example, reference to about 4% propylene oxide includes ranges between
3.6% and 4.4% i.e. 10% below or above the 4% value. This includes 3.7%, 3.8%, 3.9%, 4.0%,
4.1%, 4.2%, 4.3% and 4.4% propylene oxide.
5327735_1 (GHMatters) P88608.NZ
It is a requirement that the sterilization step is carried out for greater than 48 hours; however, as
described herein propylene oxide can also be used as a storage media and as such the
sterilization step can be carried out for at least 2, 3, 4, 5, 6, 7, 8, 9, 10 days or more.
One major benefit of the methods described herein is that the sterilization solution used herein
i.e between 3% and 6% v/v propylene oxide will not only sterilize collagen-containing tissue
without affecting the collagen fibrils, but as propylene oxide converts after about 4 days being
in contact with the biomaterial to propylene glycol (which is not toxic), the sterilized cross-
linked collagen-based biomaterial can remain in the sterilization solution well after the initial 48
hours. Indeed, it is envisaged that the cross-linked collagen-based biomaterial will be sterilized
and stored and then shipped in the same container to the end customer without the need for
further handling.
The term “sterilization” as used herein means that the cross-linked collagen-based biomaterial
satisfies the requirements under ISO 14160. ISO 14160 covers the sterilization of health care
products and pertains to liquid chemical sterilizing agents for single-use medical devices
utilizing animal tissues and their derivatives. Briefly, ISO 14160 requires tissues to be
inoculated with B. subtilis spores and then treated to remove the contamination. The
requirements for ISO 14160 trials are described in Example 6 supra.
In some embodiments, the sterilization solution is buffer-free. In other embodiments the
solution comprises de-ionized water.
The cross-linked collagen-based biomaterial, after treatment with the methods disclosed herein,
has a high level of resistance to calcification i.e. it is a “calcification-resistant biomaterial”. The
term “calcification” as used herein refers to one of the major pathological problems associated
with traditionally produced biomaterial comprising connective tissue proteins (i.e., collagen and
elastin). It has previously been shown that these materials can become calcified following
implantation within the body. Such calcification can result in undesirable stiffening or
degradation of the biomaterial. Two (2) types of calcification: intrinsic and extrinsic are known
to occur in fixed collagenous biomaterial, although the exact mechanism(s) by which such
calcification occurs is unknown. Intrinsic calcification is characterised by the precipitation of
calcium and phosphate ions within the fixed bioprosthetic tissue, including the collagen matrix
and remnant cells. Extrinsic calcification is characterised by the precipitation of calcium and
phosphate ions within adherent thrombus, including adherent cells (e.g., platelets) to the
5327735_1 (GHMatters) P88608.NZ
biomaterial and the development of calcium phosphate-containing surface plaques on the
biomaterial.
Consequently, the phrase “high level of resistance to calcification” or “calcification-resistant”
when applied to the biomaterial of the present invention means that the biomaterial, after in vivo
implantation for at least 200 days, shows less than 50 g, preferably less than 20 g, and even
more preferably less than 10 g of calcium per mg of dried tissue after its removal.
Preferably, the biomaterial of the present invention is also resistant to enzymatic degradation.
The term “resistant to enzymatic degradation” as used herein refers to the ability of the
biomaterial of the present invention to withstand enzymatic degradation to a comparable level
with traditional fixed tissue.
Once formed, the sterilized, cross-linked collagen-based biomaterial of the present invention
can then be used to treat a number of conditions and/or disorders.
Generally, the terms “treating,” “treatment” and the like are used herein to mean affecting an
individual or animal, their tissue or cells to obtain a desired pharmacological and/or
physiological effect. The effect is especially therapeutic in terms of a partial or complete cure
of a condition and/or disorder. “Treating” as used herein covers any treatment of a condition
and/or disorder in a vertebrate, a mammal, particularly a human, and includes: (a) inhibiting the
condition and/or disorder, i.e., arresting its development; or (b) relieving or ameliorating the
symptoms of the condition and/or disorder, i.e., cause regression of the symptoms of the
enzymatic degradation/condition and/or disorder.
The terms “condition” and/or “disorder” are used herein interchangeably and refers to abnormal
conditions affecting animals, including humans, which can be treated using the biomaterial of
the present invention. Accordingly, the treatment of a wound, a lesion, tissue degeneration, a
microbial infection, a burn, an ulcer, dermal condition is included in the present invention.
Moreover, the replacement of heart valves, aortic roots, aortic wall, aortic leaflets, pericardial
tissue, connective tissue, dura mater, dermal tissue, a vascular tissue, cartilage, pericardium,
ligaments, tendon blood vessels, umbilical tissue, bone tissue, fasciae, and submucosal tissue
are also encompassed.
The calcification-resistant biomaterial of the present invention may also be applied to any of a
wide variety of contacting surfaces of medical devices. Contacting surfaces include, but are not
5327735_1 (GHMatters) P88608.NZ
limited to, surfaces that are intended to contact blood, cells or other bodily fluids or tissues of
an animal, including specifically a human. Suitable contacting surfaces include one or more
surfaces of medical devices that are intended to contact blood or other tissues. The medical
devices include aneurysm coils, artificial blood vessels, artificial hearts, artificial valves,
artificial kidneys, artificial tendons and ligaments, blood bags, blood oxygenators, bone and
cardiovascular replacements, bone prostheses, bone waxes, cardiovascular grafts, cartilage
replacement devices, catheters, contact lenses, containers for cell and tissue culture and
regeneration, embolization particles, filtration systems, grafts, guide channels, in-dwelling
catheters, laboratory instruments, microbeads, nerve-growth guides, ophthalmic implants,
orthopedic implants, pacemaker leads, probes, prosthetics, shunts, stents, supports for peptides,
surgical instruments, sutures, syringes, urinary tract replacements, wound coverings, wound
dressings, wound healing devices and other medical devices known in the art.
Other examples of medical devices that would benefit from the application of the present
invention will be readily apparent to those skilled in the art of surgical and medical procedures
and are therefore contemplated by the instant invention. The contacting surface may include a
mesh, coil, wire, inflatable balloon, or any other structure which is capable of being implanted
at a target location, including intravascular locations, intralumenal locations, locations within
solid tissue, and the like. The implantable device can be intended for permanent or temporary
implantation. Such devices may be delivered by or incorporated into intravascular and other
medical catheters.
The process of coating the surfaces of such devices can be performed by the plasma coating
technique, as described in the International patent application No. WO96/24392.
By “comprising” is meant including, but not limited to, whatever follows the word comprising”.
Thus, use of the term “comprising” indicates that the listed elements are required or mandatory,
but that other elements are optional and may or may not be present. By “consisting of” is meant
including, and limited to, whatever follows the phrase “consisting of”. Thus, the phrase
“consisting of” indicates that the listed elements are required or mandatory, and that no other
elements may be present. By “consisting essentially of” is meant including any elements listed
after the phrase, and limited to other elements that do not interfere with or contribute to the
activity or action specified in the disclosure for the listed elements. Thus, the phrase “consisting
essentially of” indicates that the listed elements are required or mandatory, but that other
elements are optional and may or may not be present depending upon whether or not they affect
the activity or action of the listed elements.
5327735_1 (GHMatters) P88608.NZ
The invention will now be further described by way of reference only to the following non-
limiting examples. It should be understood, however, that the examples following are
illustrative only, and should not be taken in any way as a restriction on the generality of the
invention described above.
Example 1 Basic Processing And Storage Of Biomaterial
Harvesting of a collagen-derived biomaterial
Porcine hearts from adult pigs were harvested at a local abattoir and transported to the
laboratory on ice packs within 2 – 4 hours of death. The hearts were washed twice in ice-cold
0.9% v/v saline solution and carefully cleaned from adherent fat and loose connective tissue.
The aortic roots with the aortic valves were dissected from the hearts and placed in ice-cold
0.9% v/v saline / Phenyl-methyl-sulfonyl-fluoride (PMSF) and the valved aortic roots washed
for 20 minutes in the 0.9% v/v saline solution containing PMSF. The valve leaflets were
removed from the aortic valve orifice and stored in ice-cold 0.9% v/v saline solution.
Cross-linking (Fixation) of the biomaterial
A 0.625% v/v glutaraldehyde solution containing 9.07g/l potassium di-hydrogen phosphate
buffer in sterile, deionised water was prepared. The pH of the glutaraldehyde solution was
adjusted to 7.4 with sodium hydroxide. The aortic valve leaflets were cross-linked in the
glutaraldehyde solution at 1-5C for a minimum period of 5 days to crosslink proteins present in
the collagen of the tissues.
Rinsing the cross-linked biomaterial
The aortic valve leaflets were removed from the glutaraldehyde solution and rinsed in a sterile
0.9% v/v sodium chloride for about 15 minutes. During the rinsing period, the temperature of
the rinsing solution was maintained at approximately 10 C.
Final sterilization and storage of the biomaterial
The porcine aortic valve leaflets were immersed in a 2.0% v/v solution of glutaraldehyde
containing 29.02 g/l potassium di-hydrogen phosphate buffer in sterile, deionised water. The pH
5327735_1 (GHMatters) P88608.NZ
of the aldehyde solution was adjusted to 7.4 with sodium hydroxide. The process of sterilization
was carried out at about 25 C for 5 days. The sterilized tissues were divided into four groups
and stored in: (i) 0.625% v/v glutaraldehyde, (ii) 5.0% v/v glutaraldehyde, (iii) 10% v/v
glutaraldehyde; and (iv) 2% v/v propylene oxide until further use.
Example 2 Effect Of Storage Solution On Calcification Profile Of Biomaterial
Experimental studies in small and large animal models were conducted to assess the
effectiveness of the above-described sterilisation-storage process in mitigating calcification of
treated collagen containing biomaterials.
In the first animal study, porcine aortic valve leaflets sterilised and stored according to the
methods described in Example 1 were used for assessment in a small animal model.
Sterilised and stored porcine aortic valve leaflets of all four groups were rinsed in 0.9% v/v
saline for 5 minutes. The rinsed tissues were surgically implanted in subcutaneous pockets (one
sample of each group per rat), created in the central abdominal wall area of growing (6 weeks
old) male Wistar rats. These tissues were removed after 60 days, host tissue removed and
samples dried in a Biotherm™ incubator (Marcus Medical, JHB, RSA) at 90 C for 48 h. The
dried samples were weighed, and the calcium content extracted in 5.0ml 6 N ultrapure
hydrochloric acid (Merck, JHB, RSA) at 75 C for 24 h. The extractable calcium content was
then measured using an atomic absorption spectrophotometer (Varian AA1275) and expressed
as µg calcium per mg tissue (dry weight). These data are summarised in Table 1. Results (µg
Calcium per mg dried tissue) are summarised in Table 1.
5327735_1 (GHMatters) P88608.NZ
Table 1
Storage solution Mean ± standard error
Glutaraldehyde (0.625 %) 70.146 g Ca / mg Tissue ± 7.037
Glutaraldehyde (5.0 %) 88.439 g Ca / mg Tissue ± 4.470
Glutaraldehyde (10.0 %) 66.870 g Ca / mg Tissue ± 13.235
Propylene Oxide (2.0%) 25.311 g Ca / mg Tissue ± 5.292
5327735_1 (GHMatters) P88608.NZ
Example 3 Effect Of Sterilization & Storage Solution On Calcification Profile Of
Biomaterial
Harvesting of a collagen-derived biomaterial
In the second animal study, porcine aortic valve leaflets were harvested and isolated according
to the method described in Example I. Isolated porcine aortic valve leaflets were divided into
three groups. Group I received a typical cross-linking treatment (control); Group II received a
proprietary method of cross-linking (see WO2006/066327 incorporated herein by reference);
and Group III received the same cross-linking treatment as Group II, but this was followed by
the incubating the cross-linked biomaterial with a sterilization solution comprising about 4%
v/v propylene oxide and incubating the biomaterial between 30 C and 55 C for greater than 48
hours.
Cross-linking (Fixation) of the aortic valve leaflets
In group I, porcine aortic valve leaflets were cross-linked in a 0.625% glutaraldehyde solution
containing 9.07g/l potassium di-hydrogen phosphate buffer in sterile, deionised water was
prepared. The pH of the glutaraldehyde solution was adjusted to 7.4 with sodium hydroxide.
The aortic valve leaflets were cross-linked in the glutaraldehyde solution at 1-5C for a
minimum period of 5 days to crosslink proteins present in the collagen of the tissues.
In group II and III, a water-soluble alcohol-containing solution of 60–80% v/v by volume
alcohol ethanol was prepared. The porcine aortic valve leaflets were immersed into the alcohol
solution after overnight storage at 4 C. The valved aortic roots were immersed in the same
alcohol solution immediately after the final wash in ice-cold 0.9% v/v saline (containing 0.5mM
PMSF). The porcine aortic valve leaflets were kept in the alcohol solution at about 5 C for a
minimum of 24 hours.
The porcine aortic valve leaflets were removed from the alcohol solution and rinsed for about
minutes with 0.9% v/v saline. During the rinsing period, the temperature of the rinsing
solution was maintained at approximately 10 C.
The aortic valve leaflets were immersed in a 0.625% v/v solution of glutaraldehyde containing
9.07g/l potassium di-hydrogen phosphate buffer in sterile, deionised water. The pH of the
glutaraldehyde solution was adjusted to 7.4 with sodium hydroxide. The pericardium and the
5327735_1 (GHMatters) P88608.NZ
valved aortic roots were fixed in the glutaraldehyde solution at 1-5C for a minimum period of
24 hours to crosslink proteins present in the collagen of the tissues.
The porcine valve leaflets were removed from the glutaraldehyde solution and rinsed in a sterile
0.9% v/v sodium chloride for about 15 minutes. During the rinsing period, the temperature of
the rinsing solution was maintained at approximately 10 C.
The porcine aortic valve leaflets were then immersed in a buffer-free solution containing 8mg
dicarboxylic acid per 1ml de-ionised water volume. The pH of the solution was adjusted to a pH
of 4.5 with a volume of diluted hydrochloric acid. The pericardium and the valved aortic roots
were immersed in the solution at a temperature of about 45 C for about 48 hours.
Final sterilization and storage of the biomaterial
The porcine aortic valve leaflets were then sterilized and stored either by:
(i) immersing the tissue in a 0.25% v/v solution of glutaraldehyde containing 9.07g/l potassium
di-hydrogen phosphate buffer in sterile, deionised water. The pH of the aldehyde solution was
adjusted to 7.4 with sodium hydroxide. The process of sterilization was carried out at a
temperature about 45 C for about 120 minutes (Treatment A); or
(ii) the porcine aortic valve leaflets were sterilized in an aqueous solution comprising of 4% v/v
propylene Oxide by weight combined with 20% v/v ethyl alcohol at 37 C for about 24 hours
and stored in a 4% v/v propylene oxide solution Treatment B – present invention).
Sterilized and stored porcine aortic valve leaflets of all three groups were rinsed in 0.9% v/v
saline for 5 minutes. The rinsed tissues were surgically implanted in subcutaneous pockets (one
sample of each group per rat), created in the central abdominal wall area of growing (6 weeks
old) male Wistar rats. These tissues were removed after 60 days, host tissue removed and
samples dried in a Biotherm™ incubator (Selby Scientific, Perth, WA) at 90 C for 48 h. The
dried samples were weighed, and the calcium content extracted in 5.0ml 6 N ultrapure
hydrochloric acid (Merck, Sydney, Australia) at 75 C for 24 h. The extractable calcium content
was then measured using an atomic absorption spectrophotometer (Varian AA1275) and
expressed as µg calcium per mg tissue (dry weight). Results (µg Calcium per mg dried tissue)
are summarised in Table 2.
5327735_1 (GHMatters) P88608.NZ
Table 2
Storage solution Mean ± standard error
Glutaraldehyde (0.625 %) 174.525 g Ca / mg Tissue ± 6.884
Treatment A 0.25% Glutaraldehyde 3.300 g Ca / mg Tissue ± 0.289
Treatment B 4% propylene Oxide 1.325 g Ca / mg Tissue ± 0.317
5327735_1 (GHMatters) P88608.NZ
Example 4 Effect Of Treatment B On Calcification Profile Of Bovine Pericardium
In third animal study, the calcification potential of bovine pericardium prepared, cross-linked
and stored according to the tissues in Example 3 (0.625% buffered glutaraldehyde, Treatment A
+ 0.2% glutaraldehyde and Treatment B 4% v/v propylene oxide) was compared with the
calcification potential of commercial bovine pericardium (Hancock pericardium) stored in a
0.2% glutaraldehyde solution.
Representative samples of each group were trimmed to 1 x 1cm size and rinsed in 0.9% v/v
saline for 5 minutes. These samples were surgically implanted in subcutaneous pockets, created
in the central dorsal wall area of growing (6 weeks old) male Wistar rats. These tissues were
removed after 60 days, host tissue removed and the calcium content determined by atomic
absorption spectrophotometry. Results ( g Calcium per mg dried tissue) are summarised in
Table 3.
5327735_1 (GHMatters) P88608.NZ
Table 3
Storage solution Mean ± standard error
Glutaraldehyde (0.625 %) 136.025 g Ca/mg Tissue ± 11.385
ADAPT+ 0.25% Glutaraldehyde 4.100 g Ca/mg Tissue ± 0.204
ADAPT+ 4% v/v Propylene Oxide 1.100 g Ca/mg Tissue ± 0.147
Hancock Pericardium (in 0.2% Glutaraldehyde) 6.375 g Ca/mg Tissue ± 1.993
5327735_1 (GHMatters) P88608.NZ
Example 5 Effect Of Treatment B On Calcification Profile Of Porcine Aortic
Valve Tissue (Valve Leaflets & Aortic Wall) In A Large Animal Model
In the fourth animal study, the calcification potential of porcine aortic valve tissue (valve
leaflets and aortic wall) prepared, cross-linked in 0.625% buffered glutaraldehyde and stored in
(i) 0.625% glutaraldehyde, (ii) treated with Treatment A (0.625% glutaraldehyde) and (iii)
treated with Treatment B (4% propylene oxide).
Representative samples of each group were trimmed to an oval shaped size of approximately
1.2 x 1cm and rinsed in 0.9% saline for 5 minutes. These samples were surgically implanted in
the jugular vein of juvenile sheep (body weight 22-25 kg). These tissues were removed after
150 days, host tissue removed and the calcium content determined by atomic absorption
spectrophotometry. Results ( g Calcium per mg dried tissue) are summarised in Table 4-A
(Valve leaflets) and Table 4-B (Aortic wall).
5327735_1 (GHMatters) P88608.NZ
Table 4-A (Valve leaflets))
Storage solution Mean ± standard error
0.625 % Glutaraldehyde 211.100 g Ca / mg Tissue ± 3.134
2% Propylene Oxide 93.167 g Ca / mg Tissue ± 23.764
Treatment B (4% propylene oxide) 12.775 g Ca / mg Tissue ± 12.442
Table 4-B (Aortic wall)
Storage solution Mean ± standard error
0.625 % Glutaraldehyde 59.444 g Ca / mg Tissue ± 12.263
2% Propylene Oxide 28.633 g Ca / mg Tissue ± 8.370
Treatment B (4% propylene oxide) 18.287 g Ca / mg Tissue ± 7.305
5327735_1 (GHMatters) P88608.NZ
Example 6 Validation: Sterilisation Of Commercial Heart Valve Inoculated With
Bacillus subtilis Spores
This validation was performed to test the feasibility of sterilising commercial heart valve tissue
with 4% propylene oxide after 48 hours at 45°C. The purpose of this feasibility study was to
investigate if 3.8% propylene oxide (as a “worst-case” concentration level) is capable of
sterilising commercial heart valves X tissue under “worst-case” conditions (contamination with
Bacillus subtilis spores) prescribed by FDA regulations. The test conditions were:
The valves were removed from the 0.5% Glutaraldehyde and rinsed in a total of 1000 mls of
sterile distilled water for a total of 6 mins.
The valve holder and the valve were then aseptically separated and then dried for
approximately 30 mins or until visibly dry.
The valve holder and the valve of each device were then inoculated with a total of 20µl of a
suspension of Bacillus subtilis spores obtained from STERIS Corporation, USA. The suspension
contained 1.25 x 10 spores.
The valves were then allowed to dry for approximately 1 hour at room temperature.
The devices were then reassembled as per receipt and placed into a sterile jar.
To ten devices, 160mls of freshly prepared 3.8% propylene oxide was added.
To the final device, 160mls of Soybean-Casein Digest Medium (SCDM) was added. This was
the positive control to assess the viability of the spore suspension. The positive control was
incubated at 32°C for 48 hours.
The ten test valves were then incubated at 42°C for 44 hours.
Following incubation, a sterility test was performed on each valve.
The valves were separated and each component transferred to an empty sterile jar, to which
SCDM was added.
The jars were then incubated at 32°C for 14 days.
The jars were examined daily for signs of turbidity.
Test details:
Lab Number: 7343042W
Method: Method in accordance with Test for Sterility, Appendix XVI, British Pharmacopoeia,
2010, and Pharmaceutical Testing Facility procedure MB:PT:0110.
5327735_1 (GHMatters) P88608.NZ
Table 5
Test Results
SCDM: No growth detected after 14 days incubation at 32°C.
Stasis Test: Performed at expiration of test period. SCDM showed
visible growth of C. albicans within 48 hours.
Positive Control Growth detected after 24 hours. Growth identified as B. subtilis.
5327735_1 (GHMatters) P88608.NZ
Example 7 Effect Of Treatment B On Calcification Profile Of Commercial
Heart Valve Tissue (Bovine Pericardial Tissue) In A Small Animal Model
Table 6 shows the results of a fifth animal study in which the calcification potential of bovine
pericardium cross-linked and sterilised in 0.625% v/v glutaraldehyde (which served as a
reference control – marked A) was compared with commercial heart valve tissue (bovine
pericardium, cross-linked and stored according to a commercial proprietary protocol which is
0.625% v/v buffered glutaraldehyde cross-linking + formaldehyde storage – marked B) and the
same commercial heart valve tissue sterilised at 45°C for 48 hours in 4% v/v propylene oxide
and stored in 4% v/v propylene oxide solution – marked C.
Representative samples of each group were trimmed to 1 x 1cm size and rinsed in 0.9% v/v
saline for 5 minutes. These samples were surgically implanted in subcutaneous pockets, created
in the central dorsal wall area of growing (6 weeks old) male Wistar rats. These tissues were
removed after 8, 16 and 24 weeks, host tissue removed and the calcium content determined by
atomic absorption spectrophotometry. Results ( g Calcium per mg dried tissue) are summarised
in Table 6.
5327735_1 (GHMatters) P88608.NZ
Table 6
Storage solutions
A B C (Present Invention)
8 Weeks 85 g Ca/mg Tissue 12 12 g Ca/mg Tissue 11 0.751 g Ca/mg Tissue 0.2
16 Weeks 94 g Ca/mg Tissue 12 10 g Ca/mg Tissue 8 0.74 g Ca/mg Tissue 0.2
24 Weeks 134 g Ca/mg Tissue 12 8 g Ca/mg Tissue 6 3.56 g Ca/mg Tissue 3
5327735_1 (GHMatters) P88608.NZ
Example 8 Effect Of Treatment B On Calcification Profile Of Commercial
Heart Valve Tissue (Bovine Pericardial) Tissue In A Rapid In Vitro
Calcification Model
In a further experimental assessment, the calcification potential of commercial valve tissue
(control tissue) was compared with commercial heart valve tissue sterilised at 45°C for 48 hours
in 4% propylene oxide and stored in 4% propylene oxide solution (treated tissue) in a rapid in
vitro calcification model.
Stented commercial heart valves (control and treated) were mounted in a Rowan Ash Fatigue
tester and exposed to a physiological solution (with a high calcium/phosphate content) during
accelerated flow (400 test cycles per minute) up to 50 million cycles.
After 50 million test cycles, heart valves were removed and a represented tissue sample taken
for histology. The remaining tissue of each of the three valve leaflets in each valve were
removed and the calcium content determined by atomic absorption spectrophotometry. Results
( g Calcium per mg dried tissue) are summarised in Table 7.
5327735_1 (GHMatters) P88608.NZ
Table 7
Valve tissue Mean ± standard error
Commercial valve 49.71 g Ca/mg tissue ± 2.112
Commercial valve + 4% Propylene Oxide 32.34 g Ca/mg tissue ± 1.336
5327735_1 (GHMatters) P88608.NZ
Example 9 Effect Of Sterilization and Storage Methodology Tissue Inoculated With
Bacillus subtilis Spores
Figures 1 and 2 show the effect of 2% v/v and 4% v/v propylene oxide (respectively) at varying
temperatures between 15°C and 45°C on B. subtilis spores over time. The experiment
conditions used are described in Example 6. Essentially, it can be seen the neither sterilization
solutions (2% or 4%) has little sterilization effect before 48 hours. It can also be seen from
Figure 2 that within 48 hours the effect of increasing temperature has a profound effect on
sterilization. For example, at a temperature of 40°C and above there was sterilization after 24
hours and that by 48 hours there was sterilization even at temperatures of 25°C and above.
Figure 1 shows that in order to obtain sterilization with 2% v/v propylene oxide the tissue needs
to be incubated for at least 6 days at temperatures above 35°C. Even incubation for 10 days at
to 20°C has no material effect on sterilization with 2% v/v propylene oxide.
Thus, it can be seen from Figures 1 and 2 that optimal sterilization is obtained by incubating the
tissue with a 4% v/v propylene oxide solution and incubating the tissue at about 45 C for
greater than 48 hours.
5327735_1 (GHMatters) P88608.NZ
Claims (14)
1). A method for sterilizing a cross-linked collagen-based biomaterial comprising contacting said cross-linked collagen-based biomaterial with a sterilization solution comprising 5 between 3% and 6% v/v propylene oxide and incubating said biomaterial between 30 C and 55C for greater than 48 hours; with the proviso that the sterilization solution does not include alcohol.
2). The method of claim 1, wherein the incubation temperature is between 35C and 50 C.
3). The method of claim 1, wherein the incubation temperature is about 45 C.
4). The method of claim 1, wherein the incubation temperature after 48 hours is reduced to room temperature.
5). The method of claim 1, wherein the sterilization solution comprises between 3.8% and 4.5% v/v propylene oxide.
6). The method of claim 1, wherein the sterilization solution comprises about 4% v/v 20 propylene oxide.
7). The method of claim 1, wherein the sterilization step is carried out for 2 to 10 days or more. 25
8). The method of claim 1, wherein the collagen-based biomaterial is isolated from an animal selected from the group consisting of an ovine, a bovine, a caprine, an equine, a porcine, a marsupial and a human.
9). The method of claim 1, wherein the biomaterial is a cellular tissue selected from the 30 group consisting cardiovascular tissue, heart tissue, heart valve, aortic roots, aortic wall, aortic leaflets, pericardial tissue, connective tissue, dura mater, dermal tissue, a vascular tissue, cartilage, pericardium, ligament, tendon, blood vessels, umbilical tissue, bone tissue, fasciae, and submucosal tissue and skin. 35
10). The method of claim 9, wherein the biomaterial further comprises synthetic analogs formed from synthetic polymers, biological polymers, or both. 5327735_1 (GHMatters) P88608.NZ
11). A method for sterilizing a collagen-based biomaterial comprising: (a) providing a collagen-based biomaterial and contacting with 0.625% v/v glutaraldehyde solution and potassium di-hydrogen phosphate pH 7.4; 5 (b) incubating said biomaterial at about 1-5C for at least 5 days to produce a cross-linked collagen-based biomaterial; (c) contacting said cross-linked collagen-based biomaterial with a sterilization solution comprising between 3% and 6% v/v propylene oxide and incubating said biomaterial between 30 C and 55 C for greater than 48 hours; with the proviso that the sterilization solution 10 does not include alcohol.
12). A method of sterilizing and storing a cross-linked collagen -based biomaterial comprising contacting said cross-linked collagen-based biomaterial with a solution comprising between 3% and 6% v/v propylene oxide and incubating said biomaterial between 30 C and 15 55C for greater than 48 hours and then allowing the biomaterial to remain in contact with said propylene oxide until same converts to propylene glycol; with the proviso that the solution does not include alcohol.
13). A sterilized, cross-linked collagen-based biomaterial produced by the method of claim 20 1.
14). A container comprising a sterilized, cross-linked collagen-based biomaterial and a 3% to 6% v/v propylene glycol solution, wherein said propylene glycol has resulted from the conversion in situ of a 3% to 6% v/v propylene oxide solution while in the presence of the 25 biomaterial. 5327735_1 (GHMatters) P88608.NZ
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2011904681A AU2011904681A0 (en) | 2011-11-10 | Sterilization Process | |
AU2011904681 | 2011-11-10 | ||
US13/561,787 US20130122583A1 (en) | 2011-11-10 | 2012-07-30 | Sterilization process |
US13/561,787 | 2012-07-30 | ||
PCT/AU2012/001388 WO2013067598A1 (en) | 2011-11-10 | 2012-11-09 | Sterilization process |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ625543A NZ625543A (en) | 2015-12-24 |
NZ625543B2 true NZ625543B2 (en) | 2016-03-30 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200353126A1 (en) | Sterilization Process | |
US9205172B2 (en) | Implantable biomaterial and a method of producing same | |
JP4619597B2 (en) | Sterilization of living tissue | |
JP2003516191A (en) | Anti-calcification treatment of fixed biocompatible material | |
EP2640431A2 (en) | Double cross-linkage process to enhance post-implantation bioprosthetic tissue durability | |
US20220072202A1 (en) | Method for preparing biological tissue for surgical implantation | |
US6379615B1 (en) | Methods of sterilizing articles | |
NZ625543B2 (en) | Sterilization process |